Sinusoidal Obstruction Syndrome During Chemotherapy of Pediatric Cancers and its Successful Management With Defibrotide

Kizilocak, Hande; Dikme, Gürcan; Ozdemir, Rejin; Kurugoglu, Sebuh; Adaletli, İbrahim; Erkan, Tülay; Celkan, Tiraje

doi:10.1097/mph.0000000000000958

Sinusoidal Obstruction Syndrome During Chemotherapy of Pediatric Cancers and its Successful Management With Defibrotide

Atıf İçin Kopyala

Kizilocak H., Dikme G., Ozdemir N., Kurugoglu S., Adaletli I., Erkan T., ...Daha Fazla

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, cilt.39, sa.7, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 39 Sayı: 7
Basım Tarihi: 2017
Doi Numarası: 10.1097/mph.0000000000000958
Dergi Adı: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Sinusoidal obstruction syndrome (SOS) is a life-threatening complication generally occurring after hematopoietic stem cell transplantation. SOS after standard dose chemotherapy in malignancies is rare. Between the year 1995 and 2016, 414 patients were diagnosed with acute lymphoblastic leukemia and 113 patients were diagnosed with Wilms tumor in our institution. Among these patients, 4 patients with acute lymphoblastic leukemia (0.96%) and 2 patients with Wilms tumor (1.7%) developed SOS during treatment. SOS behaves like a local disseminated intravascular coagulation. Defibrotide has proved to be effective in SOS. In this article, we report our experience with defibrotide in SOS.